期刊文献+

T1G3期膀胱癌2种电切方式的二次电切疗效比较 被引量:2

Comparision of the second electric resection effects of two kinds of endoscopic resection in T1G3 bladder cancer
下载PDF
导出
摘要 目的:比较T1G3期膀胱癌2种电切方式的二次电切临床疗效。方法:将初次经尿道膀胱肿瘤电切术( TURBT)术后病理诊断为T1G3期膀胱癌患者82例,随机分为2组,术后4周内行第二次电切,其中38例行 TURBT,44例行经尿道等离子电切术。比较2组手术时间、术后膀胱冲洗时间、闭孔神经反射率、肌层缺失率及二次电切术后病理分期。结果:2组患者手术时间、术后膀胱冲洗时间、闭孔神经反射率和肌层缺失率差异均有统计学意义(P<0.05-P<0.01)。二次电切术后病理分期差异无统计学意义(P〉0.05)。结论:PKRBT出血少、切割层次清晰,可缩短手术时间及术后膀胱冲洗时间,降低术中闭孔神经反射,提高肿瘤病理分期准确性。 Objective:To evaluate the clinical effects of the second electric resection of two kinds of endoscopic resection in T1G3 bladder cancer. Methods:Eighty-two T1G3 bladder cancer patients diagnosed by pathological results of the first transurethral resection of bladder tumor(TURBT) were randomly divided into group A(38 cases) and group B(48 cases). Within postoperative 4 weeks,the group A and group B were treated with the second TURBT and transurethral plasma kinetic resection of bladder tumor,respectively. The time of operation and postoperative bladder irrigation, obturator nerve reflex rate, muscle layer lack rate and second postoperative pathological staging between two groups were compared. Results:The differences of the time of operation and postoperative bladder irrigation,obturator nerve reflex rate and muscle layer lack rate between two groups were statistically significant ( P 〈0. 05 to P 〈0. 01). The difference of the second postoperative pathological staging between two groups was not statistically significant(P〉0. 05). Conclusions:The TURBT is less bleeding, clear cutting layer and good clinical effects, which can short the time of operation and postoperative bladder irrigation,reduce the obturator nerve reflex and improve the accuracy of tumor pathological stage.
出处 《蚌埠医学院学报》 CAS 2015年第6期749-751,共3页 Journal of Bengbu Medical College
关键词 膀胱肿瘤 非肌层浸润性 经尿道等离子电切术 经尿道膀胱肿瘤电切术 bladder neoplasms non-muscle invasive staging transurethral plasma kinetic resection transurethral resection of bladder tumor
  • 相关文献

参考文献11

  • 1那彦群,叶章群,孙颖浩,等.2014版中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2013:36-37.
  • 2Kaufman DS, Shipley Wu, Feldman AS. Bladder Cancer [ J ]. Lancet,2009,374 ( 9685 ) : 239 - 249.
  • 3贺大林,朱国栋.T1G3期膀胱癌诊治策略[J].现代泌尿外科杂志,2012,17(1):1-5. 被引量:4
  • 4Yoshimua R, Adachi T, Fumao K, et al. Treatment of bladder tumors and benigan prostatic hyperplasia with a new TUR system using physiological saline as perfusate [ J ]. World Surg, 2006,30 (4) :473 -477.
  • 5左玉良,王朝明.经尿道膀胱肿瘤电切术中闭孔神经反射的防治[J].中华实用诊断与治疗杂志,2011,25(9):923-924. 被引量:18
  • 6Sylvester RJ, Van Der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder caner using EORTC risk tables : a combined analysis of 2 596 patients from seven EORTC trials [ J ]. Eur Urol, 2006,49 (3) :466 -477.
  • 7黄洁夫,湛海伦,杨飞,卢扬柏,周祥福.初次TURBt术后病理分期低估原因的分析及处理策略[J].中华泌尿外科杂志,2012,33(6):434-438. 被引量:25
  • 8Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update[ J]. Actas Urol Esp,2012,36(7 ) :389 -402.
  • 9Dalbagni G, Vora K, Kaaq M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer[J]. Eur Urol,2009,56(6) :903 -910.
  • 10林国太,李昌桂,张益明,邹智聪,刘英发,林元田,吴银锁.浅表性膀胱癌经尿道电切术后复发的原因及预防策略[J].第三军医大学学报,2012,34(18):1884-1887. 被引量:22

二级参考文献52

  • 1王朝明.经尿道气化电切加电切术治疗膀胱肿瘤的探讨[J].临床泌尿外科杂志,2004,19(12):754-755. 被引量:3
  • 2兰卫华,靳风烁,王洛夫,张军,孙中义,谢芳.卡介苗与丝裂霉素C膀胱灌注预防国人膀胱癌复发的比较的Meta分析[J].临床泌尿外科杂志,2006,21(2):145-148. 被引量:10
  • 3葛宏兵,朱翮嘉,蔡松良.改良电切法在TURBt术中的应用[J].中华泌尿外科杂志,2006,27(4):255-255. 被引量:10
  • 4LAMM DL, BLUMENSTEIN BA, CRISSMAN JD, et al.Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study[J]. J Urol 2000,163:1124-1129.
  • 5SOLOWAY MS, SOFER M, VAIDYA A. Contemporary management of stage T1 transitional cell carcinoma of the bladder[J]. J Urol,2002,167:1573-1583.
  • 6NIEDER AM, BRAUSI M, LAMM D, et al.Management of stage T1 tumors of the bladder: International Consensus Panel[J]. Urology,2005,66:108-125.
  • 7DENZINGER S, FRITSCHE H-M, OTTO W,et al. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2008;53:146-52.
  • 8DALBAGNI G, HERR HW, REUTER VE. Impact of a second transurethral resection on the staging of T1 bladder cancer[J]. Urology,2002,60:822-824.
  • 9LAMBERT EH, PIERORAZIO PM, OLSSON CA,et al. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy[J]. BJU Int, 2007,100:33-36.
  • 10STEIN JP, LIESKOVSKY G, COTE R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients[J]. J Clin Oncol,2001,19:666-675.

共引文献86

同被引文献21

  • 1那彦群,叶章群,孙颖浩,等.2014版中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2013:36-37.
  • 2Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer[J]. Urol Clin North Am,1992,19 (3) :435-553.
  • 3Shim JS, Choi H, Noh TI, et al. The clinical significance ofa second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study[J]. Korean J Urol, 2015,56(6) :429-434.
  • 4Divrik RT,Sahin AF,Yildirim U, et al. Impact of routine second transurethral resection on the Long-Term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and Disease- Specific survival: a prospective randomised clinical trial [J]. Eur Urol,2010,58(2) :185-190.
  • 5Grimm MO, Steinhoff C, Simon X, et al. Effect of routine repeat transurethral resection for superficial bladder canc- er:a long-term observational study[J]. J Urol, 2003,170 (2 Pt 1) :433-437.
  • 6Babjuk M,Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the blad- der:update 2013[J]. Eur Urol,2013,64(4):639-653.
  • 7Faba OR, Palou J, Breda A, et al. High-risk non-muscle- invasive bladder cancer: update for a better identification and treatment[J]. World J Urol,2012,30(6):833-840.
  • 8Drfigoescu O,Tomescu P,Pfinus A,et al. Adjuvant treat- ment of intermediate risk non-muscle invasive bladder cancer[J]. Curt Health Sci,2014,40(1) ..47-50.
  • 9Liu W,Qi L,Zu X,et al. A preoperative marker panel for the prediction of residual tumor and the decision making for repeat transurethral resection[J]. Urol Oneol, 2016, 33(4) : 165. e9-165.
  • 10K1/in R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder[J]. J Urol, 1991,146(2) : 316-318.

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部